The nociceptin receptor antagonist [Nphe1,Arg14,Lys15]nociceptin/orphanin FQ-NH2 blocks the stimulatory effects of nociceptin/orphanin FQ on the HPA axis in rats

Neuroscience

Volumn 141, Issue 4, 2006, Pages 2051-2057

  Leggett, J D ^a   Harbuz, M S ^b   Jessop, D S ^b   Fulford, A J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

ACTH; AVP; corticosterone; CRF; mRNA; POMC

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; MESSENGER RNA; NOCICEPTIN; NOCICEPTIN RECEPTOR ANTAGONIST; UFP 101; UNCLASSIFIED DRUG;

ADENOHYPOPHYSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; HISTOCHEMISTRY; HORMONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION;

ADRENOCORTICOTROPIC HORMONE; ANALYSIS OF VARIANCE; ANIMALS; CORTICOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IN SITU HYBRIDIZATION; INJECTIONS, INTRAVENTRICULAR; MALE; OPIOID PEPTIDES; PITUITARY-ADRENAL SYSTEM; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; VASODILATOR AGENTS;

EID: 33747334359     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.05.036     Document Type: Article

References (42)

1. Bewick G.A., Dhillo W.S., Darch S.J., Murphy K.G., Gardiner J.V., Jethwa P.H., Kong W.M., Ghatei M.A., and Bloom S.R. Hypothalamic cocaine- and amphetamine-regulated transcript (CART) and agouti-related protein (AgRP) neurons coexpress the NOP1 receptor and nociceptin alters CART and AgRP release. Endocrinology 146 (2005) 3526-3534
2. Blakley G.G., Pohorecky L.A., and Benjamin D. Behavioral and endocrine changes following antisense oligonucleotide-induced reduction in the rat NOP receptor. Psychopharmacology (Berl) 171 (2004) 421-428
3. Bryant W., Callahan P., Murphree E., and Janik J. [Phe(1)Psi(CH(2)-NH)Gly(2)]NC(1-13)NH(2) does not antagonize orphaninFQ/nociceptin-induced prolactin release. Brain Res Bull 57 (2002) 695-703
4. Calo G., Guerrini R., Bigoni R., Rizzi A., Marzola G., Okawa H., Bianchi C., Lambert D.G., Salvadori S., and Regoli D. Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol 129 (2000) 1183-1193
5. Calo G., Rizzi A., Rizzi D., Bigoni R., Guerrini R., Marzola G., Marti M., McDonald J., Morari M., Lambert D.G., Salvadori S., and Regoli D. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol 136 (2002) 303-311
6. Dautzenberg F.M., Wichmann J., Higelin J., Py-Lang G., Kratzeisen C., Malherbe P., Kilpatrick G.J., and Jenck F. Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198. rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. J Pharmacol Exp Ther 298 (2001) 812-819
7. Devine D.P., Watson S.J., and Akil H. Nociceptin/orphanin FQ regulates neuroendocrine function of the limbic-hypothalamic-pituitary-adrenal axis. Neuroscience 102 (2001) 541-553
8. Devine D.P., Hoversten M.T., Ueda Y., and Akil H. Nociceptin/orphanin FQ content is decreased in forebrain neurones during acute stress. J Neuroendocrinol 15 (2003) 69-74
9. Dhandapani K.M., and Brann D.W. Orphanin FQ inhibits GnRH secretion from rat hypothalamic fragments but not GT1-7 neurons. Neuroreport 13 (2002) 1247-1249
10. Fernandez F., Misilmeri M.A., Felger J.C., and Devine D.P. Nociceptin/orphanin FQ increases anxiety-related behavior and circulating levels of corticosterone during neophobic tests of anxiety. Neuropsychopharmacology 29 (2004) 59-71
11. Florin S., Suaudeau C., Meunier J.C., and Costentin J. Nociceptin stimulates locomotion and exploratory behaviour in mice. Eur J Pharmacol 317 (1996) 9-13
12. Gavioli E.C., Rae G.A., Calo G., Guerrini R., and De Lima T.C. Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test. Br J Pharmacol 136 (2002) 764-772
13. Gavioli E.C., and Calo G. Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands. Naunyn Schmiedebergs Arch Pharmacol 372 (2006) 319-330
14. Gompf H.S., Moldavan M.G., Irwin R.P., and Allen C.N. Nociceptin/orphanin FQ (N/OFQ) inhibits excitatory and inhibitory synaptic signaling in the suprachiasmatic nucleus (SCN). Neuroscience 132 (2005) 955-965
15. Guerrini R., Calo G., Bigoni R., Rizzi A., Varani K., Toth G., Gessi S., Hashiba E., Hashimoto Y., Lambert D.G., Borea P.A., Tomatis R., Salvadori S., and Regoli D. Further studies on nociceptin-related peptides. discovery of a new chemical template with antagonist activity on the nociceptin receptor. J Med Chem 43 (2000) 2805-2813
16. Harbuz M.S., and Lightman S.L. Responses of hypothalamic and pituitary mRNA to physical and psychological stress in the rat. J Endocrinol 122 (1989) 705-711
17. Harbuz M.S., Rees R.G., Eckland D., Jessop D.S., Brewerton D., and Lightman S.L. Paradoxical responses of hypothalamic corticotropin-releasing factor (CRF) messenger ribonucleic acid (mRNA) and CRF-41 peptide and adenohypophysial proopiomelanocortin mRNA during chronic inflammatory stress. Endocrinology 130 (1992) 1394-1400
18. Jenck F., Moreau J.L., Martin J.R., Kilpatrick G.J., Reinscheid R.K., Monsma Jr. F.J., Nothacker H.P., and Civelli O. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc Natl Acad Sci U S A 94 (1997) 14854-14858
19. Jenck F., Wichmann J., Dautzenberg F.M., Moreau J.L., Ouagazzal A.M., Martin J.R., Lundstrom K., Cesura A.M., Poli S.M., Roever S., Kolczewski S., Adam G., and Kilpatrick G. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1. anxiolytic profile in the rat. Proc Natl Acad Sci U S A 97 (2000) 4938-4943
20. Jessop D.S., Eckland D.J., Todd K., and Lightman S.L. Osmotic regulation of hypothalamo-neurointermediate lobe corticotrophin-releasing factor-41 in the rat. J Endocrinol 120 (1989) 119-124
21. Kakiya S., Murase T., Arima H., Yokoi H., Iwasaki Y., Miura Y., and Oiso Y. Role of endogenous nociceptin in the regulation of arginine vasopressin release in conscious rats. Endocrinology 141 (2000) 4466-4471
22. Kinoshita H., Jessop D.S., Finn D.P., and Harbuz M.S. Cyanamide-induced activation of the hypothalamo-pituitary-adrenal axis. J Neuroendocrinol 12 (2000) 255-262
23. Köster A., Montkowski A., Schulz S., Stube E.M., Knaudt K., Jenck F., Moreau J.L., Nothacker H.P., Civelli O., and Reinscheid R.K. Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc Natl Acad Sci U S A 96 (1999) 10444-10449
24. Kuzmin A., Sandin J., Terenius L., and Ogren S.O. Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors. Br J Pharmacol 141 (2004) 132-140
25. Le Cudennec C., Naudin B., Do Rego J.C., and Costentin J. Nociceptin/orphanin FQ and related peptides reduce the increase in plasma corticosterone elicited in mice by an intracerebroventricular injection. Life Sci 72 (2002) 163-171
26. Levin N., Blum M., and Roberts J.L. Modulation of basal and corticotropin-releasing factor-stimulated proopiomelanocortin gene expression by vasopressin in rat anterior pituitary. Endocrinology 125 (1989) 2957-2966
27. Mamiya T., Noda Y., Nishi M., Takeshima H., and Nabeshima T. Enhancement of spatial attention in nociceptin/orphanin FQ receptor-knockout mice. Brain Res 783 (1998) 236-240
28. McDonald J., Calo G., Guerrini R., and Lambert D.G. UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor. radioligand and GTPgamma(35)S binding studies. Naunyn Schmiedebergs Arch Pharmacol 367 (2003) 183-187
29. Meis S., and Pape H.C. Control of glutamate and GABA release by nociceptin/orphanin FQ in the rat lateral amygdala. J Physiol 532 (2001) 701-712
30. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monsarrat B., et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
31. Mogil J.S., and Pasternak G.W. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 53 (2001) 381-415
32. Mollereau C., Parmentier M., Mailleux P., Butour J.L., Moisand C., Chalon P., Caput D., Vassart G., and Meunier J.C. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 341 (1994) 33-38
33. Neal Jr. C.R., Mansour A., Reinscheid R., Nothacker H.P., Civelli O., and Watson Jr. S.J. Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurol 406 (1999) 503-547
34. Netti C., Rapetti D., Sibilia V., Pagani F., Pecile A., and Guidobono F. Endocrine effects of centrally injected nociceptin in the rat. Brain Res 938 (2002) 55-61
35. New D.C., and Wong Y.H. The ORL1 receptor. molecular pharmacology and signalling mechanisms. Neurosignals 11 (2002) 197-212
36. Nicholson J.R., Akil H., and Watson S.J. Orphanin FQ-induced hyperphagia is mediated by corticosterone and central glucocorticoid receptors. Neuroscience 115 (2002) 637-643
37. Olszewski P.K., Billington C.J., and Levine A.S. Fos expression in feeding-related brain areas following intracerebroventricular administration of orphanin FQ in rats. Brain Res 855 (2000) 171-175
38. Pomonis J.D., Billington C.J., and Levine A.S. Orphanin FQ, agonist of orphan opioid receptor ORL1, stimulates feeding in rats. Neuroreport 8 (1996) 369-371
39. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma Jr. F.J., and Civelli O. Orphanin FQ. a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270 (1995) 792-794
40. Shirasaka T., Miyahara S., Takasaki M., and Kannan H. Nociceptin/orphanin FQ and [Phe(1)psi(CH2-NH)Gly2]nociceptin(1-13)NH2 modulates the activity of hypothalamic paraventricular nucleus neurons in vitro. Brain Res 890 (2001) 147-153
41. Varty G.B., Hyde L.A., Hodgson R.A., Lu S.X., Mccool M.F., Kazdoba T.M., Del Vecchio R.A., Guthrie D.H., Pond A.J., Grzelak M.E., Xu X., Korfmacher W.A., Tulshian D., Parker E.M., and Higgins G.A. Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology (Berl) 182 (2005) 132-143
42. Young III W.S., Mezey E., and Siegel R.E. Vasopressin and oxytocin mRNAs in adrenalectomized and Brattleboro rats. analysis by quantitative in situ hybridization histochemistry. Brain Res 387 (1986) 231-241